George Pentheroudakis: Simple tool to detect tumour-agnostic potential of a cancer therapy

George Pentheroudakis, Chief Medical Officer at ESMO, shared the following post by Jean-Charles Soria on X, adding the following:

“The ETAC screener is a simple tool to detect tumour-agnostic potential of a cancer therapy. Emphasis on ‘potential’. So, if the potential is there, further clinical validation would be required.”

Quoting Jean-Charles Soria‘s post:

“Advances in precision medicine led to approval of tumour-agnostic molecularly guided therapies. The minimum requirements for claiming tumour-agnostic potential remain elusive. Different scenarios of minimum ORR, number of tumour types investigated & number of evaluable patients per tumour type were assessed for developing a screening tool for tumour-agnostic potential (i.e., the ESMO Tumour-Agnostic Classifier).”

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

Authors: C.B. Westphalen, D. Martins-Branco, J.R. Beal, Cardone,, N. Coleman, A.M. Schram, S. Halabi, S. Michiels1, C. Yap, F. André, F. Bibeau, G. Curigliano, E. Garralda, S. Kummar, R. Kurzrock, S. Limaye, S. Loges, A. Marabelle, C. Marchió, J. Mateo, J. Rodon, T. Spanic, G. Pentheroudakis, V. Subbiah

Read further.
Source: George Pentheroudakis/X and Jean-Charles Soria/X

Jean-Charles Soria serves as Amgen’s senior vice president of Oncology within Global Development. He is a medical oncologist and a professor of medicine at Paris-Saclay University. From 2017 to 2019, he was the senior vice president of Research and Development in Oncology at AstraZeneca. Additionally, Soria has authored or co-authored over 670 articles in leading international journals and has been recognized as one of the world’s most influential research scientists.